Function and Targeting of ETV6 in Ewing Sarcoma
Funded at Case Western Reserve University · NIH-11408636 · Data updated 2026-11-12
A scientist at Case Western Reserve University is studying a specific protein, ETV6, that helps a rare bone cancer called Ewing sarcoma, with the goal of finding targeted therapies that could spare healthy cells.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Case Western Reserve University NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project start | July 1, 2023 |
| Project end | August 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $249,000 |
| NIH project number | 5R00CA273523-04 |
| Project ID | NIH-11408636 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with Ewing sarcoma or related bone cancers could benefit from advances in targeted therapies arising from this research.
✕Less likely to help
Some patients may not respond to therapies targeting ETV6 or may have tumors driven by other pathways.
What this research studies
Ewing sarcoma is a tough bone cancer that mostly affects kids and young adults. The project will look at how ETV6 helps these cancer cells stay alive and how to block its function in a way that leaves normal cells unharmed. Researchers will use high-throughput genetics and single-cell RNA sequencing to map the detailed mechanisms and cancer cell states linked to ETV6. By combining these data, they aim to identify precise ways to disrupt ETV6 and develop potent, specific treatments for patients with this disease.
Why it matters
Potential benefit: If successful, the work could lead to new targeted therapies for Ewing sarcoma that are highly potent against cancer cells but spare normal tissues.
How similar studies have gone: Previous CRISPR and single-cell studies suggest ETV6 is a promising, cancer-biased vulnerability in Ewing sarcoma, supporting potential for impactful results.
Where this research is happening
-
Case Western Reserve University
Cleveland, United States Active
Researchers
- Principal investigator: Gao, Yuan — Case Western Reserve University
- Study coordinator: Gao, Yuan
Related research
Other NIH-funded projects on the same topics.
-
AI-powered prognostic model for Ewing sarcoma using digital pathology
Researchers are building an AI tool to predict survival for children and adults with Ewing sarcoma using digitized pathology slides.
-
RAPID: A patient-centered, fast-tracked drug trial platform for young people with relapsed Ewing sarcoma and DSRCT
A patient-friendly, open-label phase 2 platform trial tests promising drug combinations for teens and young adults whose Ewing sarcoma or DSRCT has come back or not responded to treatment.
-
TGFβ brakes immune evasion and metastasis in Ewing sarcoma during radiation
A physician-scientist will study whether blocking TGFβ during radiation can help CAR T cells fight Ewing sarcoma and improve patient outcomes.
-
Targeting immune markers in Ewing Sarcoma to guide safer, more effective therapies
A funded project at Stanford aims to use immune markers on Ewing Sarcoma to develop targeted immunotherapies that work in children and adults with this cancer.
-
Ewing sarcoma: how DNA repair weaknesses affect risk and treatment
A clinician-researcher team at Dana-Farber is studying how DNA damage repair weaknesses help drive Ewing sarcoma in kids and teens, with the goal of better predicting risk and guiding therapy.
-
Novel OTUD7A inhibitors to treat Ewing sarcoma
A scientist team is developing new small-molecule drugs that block OTUD7A to slow or stop Ewing sarcoma in children and young adults.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.